Cell viability in HepG2 cells: HepG2 cells were pre-treated with lovastatin for 24h before everolimus was added, and the combination of both drugs was incubated for 48h (A) or 120h... by Svenja Nölting (566453)

“…(A) Treatment with 5–20 μM lovastatin or with 10 nM everolimus alone significantly decreased HepG2 cell viability. …”

Strong matrix metalloproteinase (MMP)-2/9-related near-infrared fluorescent (NIRF) signal in and around the ligated area of the left common carotid artery (LCA) of ApoE<sup>-/-</su... by Ik Jae Shin (387313)

“…<p>Two weeks after partial ligation of the LCA, there is a gradient of MMP-related fluorescence (mean intensity / tissue area in a rectangular region of interest) that is maximal close to the ligation site / bifurcation point (A, LCA C1 or C2), and progressively decreased as one move inferiorly closer to the arch both on the right and on the left, but the maximum is much higher on the ligated left side (A and B). …”

Image_1_Pooled human bone marrow-derived mesenchymal stromal cells with defined trophic factors cargo promote dermal wound healing in diabetic rats by improved vascularization and... by Hélène Willer (13271226)

“…This decision-making study now enables the validation of pooled hMSCs as treatment for impaired wound healing in large randomized clinical trials.</p>…”

Table_1_Pooled human bone marrow-derived mesenchymal stromal cells with defined trophic factors cargo promote dermal wound healing in diabetic rats by improved vascularization and... by Hélène Willer (13271226)

“…This decision-making study now enables the validation of pooled hMSCs as treatment for impaired wound healing in large randomized clinical trials.</p>…”

Short-term beat-to-beat temporal variability of the RR (STV_RR) and QT (STV_QT) intervals in age-matched controls and professional soccer players before and fol... by Csaba Lengyel (353113)

“…<p>Soccer players had a significantly higher STV_RR compared to controls before the game. …”

Data Sheet 1_Application of machine learning based on habitat imaging and vision transformer to predict treatment response of locally advanced esophageal squamous cell carcinoma fo... by Shu-Han Xie (17902661)

“…</p>Conclusion<p>The ExtraTrees model leveraging habitat imaging and ViT offered a non-invasive and accurate method to predict pathological response to nICT, guiding personalized treatment strategies, and decreasing the risk of immune-related adverse effects.…”

Table_3_Effects of Sodium-Glucose Cotransporter Inhibitor/Glucagon-Like Peptide-1 Receptor Agonist Add-On to Insulin Therapy on Glucose Homeostasis and Body Weight in Patients With... by Yoon Ji Kim (136886)

“…In patients with T1D, insulin+sotagliflozin decreased the HbA1c level, daily insulin dose, and body weight without hypoglycemia compared with insulin monotherapy. …”

Image_7_Effects of Sodium-Glucose Cotransporter Inhibitor/Glucagon-Like Peptide-1 Receptor Agonist Add-On to Insulin Therapy on Glucose Homeostasis and Body Weight in Patients With... by Yoon Ji Kim (136886)

“…In patients with T1D, insulin+sotagliflozin decreased the HbA1c level, daily insulin dose, and body weight without hypoglycemia compared with insulin monotherapy. …”

Table_2_Effects of Sodium-Glucose Cotransporter Inhibitor/Glucagon-Like Peptide-1 Receptor Agonist Add-On to Insulin Therapy on Glucose Homeostasis and Body Weight in Patients With... by Yoon Ji Kim (136886)

“…In patients with T1D, insulin+sotagliflozin decreased the HbA1c level, daily insulin dose, and body weight without hypoglycemia compared with insulin monotherapy. …”

Image_1_Effects of Sodium-Glucose Cotransporter Inhibitor/Glucagon-Like Peptide-1 Receptor Agonist Add-On to Insulin Therapy on Glucose Homeostasis and Body Weight in Patients With... by Yoon Ji Kim (136886)

“…In patients with T1D, insulin+sotagliflozin decreased the HbA1c level, daily insulin dose, and body weight without hypoglycemia compared with insulin monotherapy. …”

Image_8_Effects of Sodium-Glucose Cotransporter Inhibitor/Glucagon-Like Peptide-1 Receptor Agonist Add-On to Insulin Therapy on Glucose Homeostasis and Body Weight in Patients With... by Yoon Ji Kim (136886)

“…In patients with T1D, insulin+sotagliflozin decreased the HbA1c level, daily insulin dose, and body weight without hypoglycemia compared with insulin monotherapy. …”

Image_4_Effects of Sodium-Glucose Cotransporter Inhibitor/Glucagon-Like Peptide-1 Receptor Agonist Add-On to Insulin Therapy on Glucose Homeostasis and Body Weight in Patients With... by Yoon Ji Kim (136886)

“…In patients with T1D, insulin+sotagliflozin decreased the HbA1c level, daily insulin dose, and body weight without hypoglycemia compared with insulin monotherapy. …”

Image_6_Effects of Sodium-Glucose Cotransporter Inhibitor/Glucagon-Like Peptide-1 Receptor Agonist Add-On to Insulin Therapy on Glucose Homeostasis and Body Weight in Patients With... by Yoon Ji Kim (136886)

“…In patients with T1D, insulin+sotagliflozin decreased the HbA1c level, daily insulin dose, and body weight without hypoglycemia compared with insulin monotherapy. …”

Image_2_Effects of Sodium-Glucose Cotransporter Inhibitor/Glucagon-Like Peptide-1 Receptor Agonist Add-On to Insulin Therapy on Glucose Homeostasis and Body Weight in Patients With... by Yoon Ji Kim (136886)

“…In patients with T1D, insulin+sotagliflozin decreased the HbA1c level, daily insulin dose, and body weight without hypoglycemia compared with insulin monotherapy. …”

Image_9_Effects of Sodium-Glucose Cotransporter Inhibitor/Glucagon-Like Peptide-1 Receptor Agonist Add-On to Insulin Therapy on Glucose Homeostasis and Body Weight in Patients With... by Yoon Ji Kim (136886)

“…In patients with T1D, insulin+sotagliflozin decreased the HbA1c level, daily insulin dose, and body weight without hypoglycemia compared with insulin monotherapy. …”

Image_5_Effects of Sodium-Glucose Cotransporter Inhibitor/Glucagon-Like Peptide-1 Receptor Agonist Add-On to Insulin Therapy on Glucose Homeostasis and Body Weight in Patients With... by Yoon Ji Kim (136886)

“…In patients with T1D, insulin+sotagliflozin decreased the HbA1c level, daily insulin dose, and body weight without hypoglycemia compared with insulin monotherapy. …”

Image_3_Effects of Sodium-Glucose Cotransporter Inhibitor/Glucagon-Like Peptide-1 Receptor Agonist Add-On to Insulin Therapy on Glucose Homeostasis and Body Weight in Patients With... by Yoon Ji Kim (136886)

“…In patients with T1D, insulin+sotagliflozin decreased the HbA1c level, daily insulin dose, and body weight without hypoglycemia compared with insulin monotherapy. …”

Table_1_Effects of Sodium-Glucose Cotransporter Inhibitor/Glucagon-Like Peptide-1 Receptor Agonist Add-On to Insulin Therapy on Glucose Homeostasis and Body Weight in Patients With... by Yoon Ji Kim (136886)

“…In patients with T1D, insulin+sotagliflozin decreased the HbA1c level, daily insulin dose, and body weight without hypoglycemia compared with insulin monotherapy. …”

Data_Sheet_1_Comparison of Postnatal Growth Charts of Singleton Preterm and Term Infants Using World Health Organization Standards at 40–160 Weeks Postmenstrual Age: A Chinese Sing... by Li Zhang (8200)

“…This retrospective cohort study, conducted in the First Affiliated Hospital of Shandong First Medical University in Jinan China, aimed to compare the postnatal growth charts of singleton preterm and term infants using WHO standards at 40–160 weeks postmenstrual age (PMA). A total of 5,459 and 15,185 sets of longitudinal measurements [length/height, weight, head circumference (HC), and body mass index (BMI)] from birth to 160 weeks PMA were used to construct growth charts for 559 singleton preterm (mean PMA at birth, 33.84 weeks) and 1,596 singleton term infants (born at 40 weeks PMA), respectively, using the Generalized Additive Models for Location, Scale, and Shape (GAMLSS) method. …”

Image_1_The Role of Lactate Exercise Test and Fasting Plasma C-Peptide Levels in the Diagnosis of Mitochondrial Diabetes: Analysis of Clinical Characteristics of 12 Patients With M... by Yuan Zhao (336512)

“…The fasting plasma C-peptide levels decreased as a negative exponential function with disease progression (Y= 1.343*e^-0.07776X, R² = 0.4154). …”